EMERYVILLE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the third quarter of 2015. The company reported a net loss attributable to common stockholders of $14.9 million, or $0.81 per share, for the quarter ended September 30, 2015. In the same period last year, the company reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share. Adamas ended the current quarter with $132.6 million in cash, cash equivalents, and available-for-sale securities compared to $158.7 million at December 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
